vTv Therapeutics (NASDAQ: VTVT) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare vTv Therapeutics to similar companies based on the strength of its analyst recommendations, dividends, profitability, risk, institutional ownership, earnings and valuation.
Volatility & Risk
vTv Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, vTv Therapeutics’ peers have a beta of 6.57, indicating that their average share price is 557% more volatile than the S&P 500.
Insider and Institutional Ownership
11.1% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 0.8% of vTv Therapeutics shares are owned by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of recent recommendations for vTv Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|vTv Therapeutics Competitors||767||3069||11274||227||2.71|
vTv Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 161.08%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.82%. Given vTv Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe vTv Therapeutics is more favorable than its peers.
Earnings and Valuation
This table compares vTv Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|vTv Therapeutics||$119,000.00||-$52.99 million||-3.76|
|vTv Therapeutics Competitors||$263.26 million||$68.25 million||-6.41|
vTv Therapeutics’ peers have higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares vTv Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|vTv Therapeutics Competitors||-5,190.08%||-442.48%||-42.03%|
vTv Therapeutics peers beat vTv Therapeutics on 7 of the 12 factors compared.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
What are top analysts saying about vTv Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for vTv Therapeutics Inc. and related companies.